Location of oral lesions predicts treatment resistance in pemphigus vulgaris

1 Mason JM, Thomas KS, Ormerod AD et al.; U.K. Dermatology Clinical Trials Network’s STOP GAP Team. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol 2017; 177:1527–36. 2 Ormerod AD, Thomas KS, Craig FE et al.; UK Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015; 350:h2958. 3 National Institute for Health and Care Excellence. Social Value Judgements: Principles for the Development of NICE Guidance. London: NICE, 2008. 4 National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE, PMG9 2013. 5 Phillips C. What is a QALY? Newmarket: Hayward Group Ltd, 2009.

[1]  M. Mansuri,et al.  The catalase gene promoter and 5ʹ‐untranslated region variants lead to altered gene expression and enzyme activity in vitiligo , 2017, The British journal of dermatology.

[2]  S. Kumar,et al.  Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris , 2017, The British journal of dermatology.

[3]  Jo Lambert,et al.  Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants , 2016, Nature Genetics.

[4]  S. Dogra,et al.  Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris. , 2015, JAMA dermatology.

[5]  M. Gdalevich,et al.  Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis , 2014, American Journal of Clinical Dermatology.

[6]  C. Martins,et al.  Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil* , 2014, Anais brasileiros de dermatologia.

[7]  S. Dertlioğlu,et al.  No association between catalase (CAT) gene polymorphisms and susceptibility to vitiligo in a Turkish population. , 2013, La Clinica terapeutica.

[8]  M. Picardo,et al.  Guidelines for the management of vitiligo: the European Dermatology Forum consensus , 2013, The British journal of dermatology.

[9]  B. Ebrahimi,et al.  The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study , 2012, Journal of research in pharmacy practice.

[10]  N. Santos,et al.  Refractory pemphigus vulgaris associated with herpes infection: case report and review. , 2011, Revista do Instituto de Medicina Tropical de Sao Paulo.

[11]  T. Gao,et al.  Promoter variant in the catalase gene is associated with vitiligo in Chinese people. , 2010, The Journal of investigative dermatology.

[12]  G. Dell’Aversana Orabona,et al.  Adjuvant triamcinolone acetonide injections in oro‐pharyngeal pemphigus vulgaris , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  E Panzig,et al.  In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. , 1999, The journal of investigative dermatology. Symposium proceedings.

[14]  J. Wood,et al.  Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. , 1995, Dermatology.